Loading clinical trials...

TERMINATED

A Long-term Follow-up Study of Patients Who Received VOR33

NCT05309733•Vor Biopharma

Summary

VOR33 long-term follow-up (LTFU) study

Detailed Description

VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•A patient is included in this study if he/she:
•1. Has received any part of or all of a VOR33 infusion

Locations (11)

University of California San Diego Moores Cancer Center

La Jolla, California, United States

Miami Cancer Institute

Miami, Florida, United States

National Institutes of Health, Clinical Center

Bethesda, Maryland, United States

Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University Hospitals Seidman Cancer Center

Cleveland, Ohio, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Key Dates

Start Date

April 15, 2022

Primary Completion Date

May 28, 2025

Completion Date

May 28, 2025

Last Updated

July 29, 2025

Enrollment

ACTUAL participants

Conditions

Leukemia, Myeloid, Acute

Interventions

VOR33

GENETIC

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222

Leukemia, Myeloid, Acute

View study

RECRUITING

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

NCT06580106

Leukemia, Myeloid, Acute

View study

RECRUITINGPHASE1

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Long-term Follow-up Study of Patients Who Received VOR33

Inclusion Criteria

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

Interest of Light Therapy in Hematology - The PHOTO-TREAT Study